Samumed Closes $438M Series A-6

Samumed, LLC, announced today that it has closed its A-6 Round of equity issuance with $438 million, bringing its total equity raised to date to more than $650 million. The pre-money valuation for the round was $12 billion.

"We appreciate the strong support from our investors," said Osman Kibar, Ph.D., Chief Executive Officer of Samumed, "We are now in a fortunate position to both move our later stage programs to commercialization, as well as expand on our earlier stage science and clinical portfolio."

About Samumed
Samumed's small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases.